Resources
An analytical immunology laboratory performs an Enzyme-Linked Immunosorbent Assay (ELISA) to monitor antibody titers in two clinical cohorts exposed to hepatitis A virus (HAV): Cohort 1 received intramuscular pooled human immune globulin (HNIG, passive immunization) post-exposure; Cohort 2 received a two-dose inactivated HAV vaccine (active immunization) at and . Serum samples collected at , , and are serially diluted () to determine the endpoint titer (reciprocal of highest dilution with optical density ). (a) Predict the relative endpoint titers (e.g., High, Moderate, or Undetectable/Baseline) for Cohort 1 versus Cohort 2 at each of the three time points (, , ). (b) Following an in vitro re-stimulation assay of peripheral blood mononuclear cells (PBMCs) isolated at with inactivated HAV antigen, identify which cohort will exhibit robust incorporation (cell proliferation) and interferon-gamma () secretion, and justify your answer based on memory cell establishment.
Answer and steps
Final answer
(a) Cohort 1 (Passive): at , at , at . Cohort 2 (Active): at , at , at . (b) Only Cohort 2 will demonstrate significant incorporation and secretion because active vaccination induced antigen-specific central and effector memory T cells and memory B cells capable of anamnestic reactivation; Cohort 1 received only donor immunoglobulins without host lymphocyte activation, leaving their PBMC population devoid of HAV-specific memory cells.
Steps
Antibody Titers Over Time
Mechanisms of Active vs. Passive Immunity
Immunity to pathogens can be acquired actively or passively, leading to distinct kinetics of antibody longevity and immunological memory:
- Passive Immunity (Cohort 1): Involves the direct transfer of preformed exogenous immunoglobulins (e.g., pooled human normal immune globulin, HNIG).
- The recipient's immune system is bypassed; endogenous B cells and T cells are not activated.
- Circulating donor antibodies (primarily ) decay naturally according to their biological half-life ().
- No immunological memory cells (memory B cells, memory T cells, or long-lived plasma cells) are formed.
- Active Immunity (Cohort 2): Involves the administration of pathogen-derived antigens (e.g., inactivated hepatitis A virus vaccine).
- Antigens are captured and presented by antigen-presenting cells (APCs) to naive helper T () cells, which stimulate antigen-specific B cells.
- B cells undergo clonal selection, somatic hypermutation, affinity maturation, and class switching in germinal centers.
- A primary dose induces moderate antibody production and primes memory cells. A booster dose at triggers a secondary (anamnestic) response, generating high titers of high-affinity antibodies and long-lived memory T and B cells.
Step-by-Step Derivation
-
At :
- Cohort 1: Donor has undergone approximately one half-life. A substantial fraction remains in circulation, yielding a Moderate titer (typically ).
- Cohort 2: The primary immune response to the initial dose is fully developed, yielding a Moderate serum antibody titer (typically ).
-
At :
- Cohort 1: Over half-lives have elapsed since injection. The infused antibodies have been catabolized to negligible levels, resulting in an Undetectable/Baseline titer ().
- Cohort 2: Administration of the booster dose stimulates rapid differentiation of memory B cells into antibody-secreting plasma cells, producing a High endpoint titer ().
-
At :
- Cohort 1: Remains Undetectable/Baseline () because no host cells were programmed to synthesize anti-HAV antibodies.
- Cohort 2: Bone marrow-resident long-lived plasma cells continue constitutive antibody secretion, maintaining a High/Persistent protective titer (typically ).
Cell Proliferation and Cytokine Secretion in Recall Assay
- Proliferation ( incorporation): When peripheral blood mononuclear cells (PBMCs) containing antigen-specific memory T cells encounter the recall antigen in vitro, the T-cell receptors (TCRs) recognize HAV peptides displayed on MHC molecules. This stimulates clonal expansion; proliferating cells synthesize DNA and incorporate radioactive .
- Effector Cytokine () Secretion: Activated memory () and T cells rapidly secrete interferon-gamma () to orchestrate antiviral defenses.
-
Comparison:
- Cohort 2 will exhibit robust incorporation and elevated release because the active vaccination established a pool of circulating HAV-specific memory T cells and memory B cells capable of immediate reactivation.
- Cohort 1 will show no significant response above background. The passive infusion of antibodies conferred temporary humoral neutralization without priming host T or B lymphocytes, leaving the host's PBMC compartment devoid of HAV-specific memory cells.
Typical errors
01 The student confuses passive and active immunity mechanisms, incorrectly assuming passive antibody transfer confers long-term immunological memory.
Sample Student Work
Reviewed by ACEpath TeacherStep-by-Step Review
Walk Through It with Your Teacher- Step 1
: Cohort High, Cohort Moderate : Cohort Moderate, Cohort Moderate : Cohort High, Cohort High
Correct: Cohort Moderate, Cohort Moderate; : Cohort Undetectable/Baseline, Cohort High; : Cohort Undetectable/Baseline, Cohort High/Persistent
You predicted that Cohort maintains moderate titers at and reaches high titers at . In reality, passively transferred donor has a biological half-life of approximately and is cleared within a few months, becoming undetectable by . For Cohort , the booster at triggers an anamnestic response yielding a High titer that persists through .
- Step 2
Both Cohort and Cohort will exhibit proliferation and secretion. Receiving anti-HAV antibodies programs the recipient's immune system to remember HAV, leading to memory cell establishment and recall responses in both groups.
CorrectOnly Cohort will exhibit robust incorporation and secretion. Active vaccination presents antigen to host lymphocytes, generating antigen-specific memory B and T cells. Passive administration of antibodies does not activate host B or T cells and creates zero immunological memory.
You stated that receiving preformed antibodies programs the host immune system to establish memory cells. Passive transfer of immunoglobulins bypasses host antigen presentation and clonal selection, meaning Cohort has no HAV-specific memory T or B cells to proliferate or secrete upon re-stimulation.
WHAT YOU DID WELL
Compliments from Your TeacherYou recognized that active vaccination in Cohort 2 leads to protective antibody production and memory cell recall.
THE ERROR
Where Your ACEpath Teacher Spotted the MistakePredicting an increase in Cohort 1 antibody titers at 24 months despite no secondary antigen exposure or vaccination.
WHY IT HAPPENED
ACEpath Teacher's DiagnosisYou treated passively transferred immunoglobulins as an active stimulus that educates host lymphocytes. Exogenous antibodies are simply circulating proteins that clear via natural catabolism; they do not trigger TCR/BCR engagement, clonal expansion, or differentiation into memory B or T cells.
REASONING PATH
Your ACEpath teacher’s suggested approach- Mechanisms of Immunity
Active immunity requires host exposure to antigen, stimulating clonal selection and memory cell generation. Passive immunity supplies preformed antibodies, providing immediate but transient protection without activating host lymphocytes.
Check whether the intervention administers an antigen (active) or preformed antibodies (passive) before predicting long-term titers or memory responses.
- Antibody Half-Life vs. Sustained Titers
Injected decays exponentially according to its half-life () and reaches baseline within unless host plasma cells actively synthesize new antibodies.
Model passive antibody levels as an exponential decay toward zero, reserving sustained or rising titers for hosts undergoing active B-cell responses.
CORRECTED PATH
ACEpath Teacher's DemonstrationPassive antibodies (Cohort 1) undergo exponential decay (): Moderate at , Undetectable at , Undetectable at .
Active vaccination (Cohort 2) primes naive cells by (Moderate), mounts a robust secondary response following the boost (High), and maintains titers via long-lived plasma cells at (High/Persistent).
In vitro PBMC recall with HAV antigen requires host memory T cells: only Cohort 2 possesses antigen-specific memory T cells to drive incorporation and secretion.
(a) Cohort 1: Moderate at , Undetectable/Baseline at , Undetectable/Baseline at . Cohort 2: Moderate at , High at , High/Persistent at . (b) Only Cohort 2 will exhibit proliferation and secretion because active immunization establishes antigen-specific memory T and B cells, whereas passive antibody infusion does not stimulate host lymphocyte memory.
02 The student misjudges the clearance kinetics of passive antibodies, believing injected IgG persists at high titers for years without a host cellular response.
Sample Student Work
Reviewed by ACEpath TeacherStep-by-Step Review
Walk Through It with Your Teacher- Step 1Correct
Cohort 1 (Passive): , , . Cohort 2 (Active): , , .
Passively infused donor has a serum half-life of only and is not renewed by host plasma cells, meaning Cohort 1 titers drop to undetectable levels by and remain baseline at . Furthermore, the scheduled booster dose given at to Cohort 2 triggers an anamnestic secondary response, raising its titer to High at rather than remaining Moderate.
- Step 2
Cohort 2 will exhibit robust proliferation and secretion. Active vaccination induces antigen-specific memory T cells and B cells, whereas passive immunoglobulin therapy transfers preformed antibodies without generating host memory cells.
WHAT YOU DID WELL
Compliments from Your TeacherYou correctly identified that only Cohort 2 will exhibit robust proliferation and cytokine release in the in vitro re-stimulation assay.
You clearly distinguished the fundamental difference in memory cell generation between active vaccination and passive antibody transfer.
THE ERROR
Where Your ACEpath Teacher Spotted the Mistakenone
WHY IT HAPPENED
ACEpath Teacher's DiagnosisYou treated passively administered immunoglobulins as persistent circulating proteins over multi-year intervals, ignoring the natural catabolic half-life of IgG antibodies and the requirement of host plasma cells for ongoing antibody replenishment.
REASONING PATH
Your ACEpath teacher’s suggested approach- Biological Half-Life of Passive IgG
Exogenous antibodies are finite circulating proteins that decay exponentially according to their biological half-life () without ongoing host synthesis.
Calculate elapsed half-lives for passive transfers: after (around ), residual donor antibody concentration falls below diagnostic thresholds ().
- Kinetics of Booster Immunization
A secondary (booster) antigen exposure rapidly activates primed memory B cells, generating a high-affinity, high-titer secondary antibody spike.
Recognize scheduled vaccine booster time points (such as dose 2 at ) as immediate catalysts for High antibody titers rather than static moderate levels.
CORRECTED PATH
ACEpath Teacher's DemonstrationEvaluate Cohort 1 (Passive) over time: at , donor has completed approximately one half-life (), leaving a Moderate titer (). By and , the donor immunoglobulins have been completely cleared by normal protein catabolism, resulting in Undetectable/Baseline titers ().
Evaluate Cohort 2 (Active) over time: at , the primary response produces a Moderate titer (). At , the second vaccine dose acts as an anamnestic booster, driving titers to High (). At , long-lived plasma cells maintain a High/Persistent titer ().
Retain your correct response for part (b): Cohort 2 exhibits robust incorporation and secretion due to the reactivation of vaccine-induced memory T and B cells.
(a) Cohort 1: , , . Cohort 2: , , . (b) Cohort 2, because active immunization primes host memory T and B cells, whereas passive immunization transfers transient antibodies without establishing memory cells.
Lock it in
Does the passive administration of therapeutic antibodies (e.g., antivenom or IVIG) generate antigen-specific memory B or T cells?
No. Passive immunity provides immediate, transient effector antibodies without engaging host antigen-presenting cells or stimulating clonal selection of host lymphocytes.
Similar question
A newborn acquires maternal IgG antibodies across the placenta against measles virus. At of age, the child has not yet received the MMR vaccine. Predict whether the child possesses protective measles antibody titers at , and explain why based on immunoglobulin kinetics.
Answer
The child will not have protective titers. Transplacentally transferred maternal decays with a half-life of approximately and becomes undetectable by . Because passive transfer does not prime host infant B or T cells, no endogenous antibodies or memory cells remain.
Two individuals are exposed to rabies virus. Patient A receives rabies vaccine alone (active). Patient B receives both rabies immune globulin (RIG, passive) on day 0 and the full rabies vaccine series (active) on days 0, 3, 7, and 14. Compare their serum neutralizing antibody sources at day 2 versus day 90.
Answer
At day 2, Patient B has protective titers derived from the infused passive RIG, whereas Patient A has negligible titers because primary active B-cell activation takes . At day 90, the RIG in Patient B has been catabolized, and both patients maintain protective titers synthesized entirely by endogenous long-lived plasma cells generated from active vaccination.
In an experimental trial, mice in Group X receive purified polyclonal anti-ovalbumin (OVA) antibodies, while mice in Group Y are immunized with OVA protein emulsified in alum adjuvant. Six months later, splenocytes from both groups are isolated and cultured with OVA peptide. Predict the relative concentrations of IL-2 and incorporation of BrdU (a thymidine analog) in the two splenocyte cultures.
Answer
Group Y splenocytes will show high IL-2 secretion and robust BrdU incorporation, reflecting clonal expansion of OVA-specific memory helper T cells primed by active immunization. Group X splenocytes will show background levels for both markers because passive antibody transfer never activated or expanded antigen-specific host T cells.